

1 **Determining Size-Specific Dose Estimates for Helical Head CT Examinations Using Monte Carlo**
2 **Methods**

3
4 Anthony J. Hardy^{1,2}; Maryam Bostani, Ph.D^{1,2}; Andrew M. Hernandez, Ph.D³; Maria Zankl, MSc⁴;
5 Cynthia McCullough, Ph.D⁵; Chris Cagnon, Ph.D^{1,2}; John M. Boone, Ph.D³; Michael McNitt-Gray,
6 Ph.D^{1,2}
7

8 ¹Department of Radiology, David Geffen School of Medicine, University of California, Los Angeles, Los
9 Angeles, California, 90024

10 ²Physics and Biology in Medicine Graduate Program, David Geffen School of Medicine, University of
11 California, Los Angeles, Los Angeles, California, 90024

12 ³Departments of Radiology and Biomedical Engineering, Biomedical Engineering Graduate Group,
13 University of California Davis, Sacramento, California 95817

14 ⁴Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Research
15 Unit Medical Radiation Physics and Diagnostics, Ingolstaedter Landstrasse 1, Neuherberg 85764,
16 Germany

17 ⁵Department of Radiology, Mayo Clinic, Rochester, MN, 55905

18
19 ***Corresponding Author**

20 924 Westwood Blvd, Suite 650
21 Los Angeles, CA 90024, USA
22 Phone: (310) 481-7558
23 ahardy@mednet.ucla.edu

24

25

26

27

28

29

30 **Purpose**

31 Size Specific Dose Estimates (SSDE) conversion factors have been determined by AAPM Report 204 to
32 adjust $CTDI_{vol}$ to account for patient size but were limited to body CT exams. The purpose of this work was
33 to determine conversion factors that could be used for an SSDE for helical, head CT examinations for
34 patients of different sizes.

35

36 **Methods**

37 Validated Monte Carlo (MC) simulation methods were used to estimate dose to the center of the scan
38 volume from a routine, helical head exam for a group of patient models representing a range of ages and
39 sizes. Ten GSF/ICRP voxelized phantom models and five pediatric voxelized patient models from CT
40 image data were used in this study. CT scans were simulated using a Siemens MDCT equivalent source
41 model. Scan parameters were taken from the AAPM Routine Head protocols for a helical protocol and scan
42 lengths were adapted to the anatomy of each patient model. MC simulations were performed using mesh
43 tallies to produce voxelized dose distributions for the entire scan volume of each model. Three tally regions
44 were investigated: (1) a small 0.6 cc volume at the center of the scan volume, (2) 0.8-1.0 cm axial slab at
45 the center of the scan volume, and (3) the entire scan volume. Mean dose to brain parenchyma in all three
46 regions was calculated. Mean cortical bone dose and a mass-weighted average dose consisting of brain
47 parenchyma and cortical bone were also calculated for the entire scan volume and for the slab in the central
48 plane. All dose measures were then normalized by $CTDI_{vol}$ for 16 cm phantom. Conversion factors were
49 determined by calculating the relationship between normalized doses and water equivalent diameter (D_w).
50 Conversion factors for brain parenchyma and mass-weighted average were then compared with AAPM
51 Report 204 conversion factors using 16 cm CTDI phantom.

52

53 **Results**

54 Brain parenchyma dose values within the 0.6 cc volume, 0.8-1.0 cm central axial slab, and the entire scan
55 volume, when normalized by $CTDI_{vol}$ and parameterized by D_w , had an exponential relationship with a
56 coefficient of determination of 0.86, 0.84, and 0.88, respectively. There was no statistically significant
57 difference between the conversion factors across the three tally regions based on 16 cm $CTDI_{vol}$ in AAPM
58 Report 204 and normalized brain parenchyma doses for all three regions. Exponential relationships between
59 $CTDI_{vol}$ -normalized mean cortical bone had coefficients of determination of 0.83 and 0.87 for the central
60 slab and for the entire scan volume, respectively. $CTDI_{vol}$ -normalized mass-weighted average doses had
61 coefficients of determination of 0.39 and 0.51 for the central slab and for the entire scan volume,
62 respectively. A significant difference was observed between AAPM Report 204 conversion factors and
63 normalized mass-weighted average for the central slab and entire scan volume.

64

65 **Conclusions**

66 Conversion factors that could be used for an SSDE for routine, helical head CT exams were determined for
67 two different interpretations of center of scan volume that represent normalized dose as a function of head
68 size using D_w . AAPM Report 204 conversion factors based on 16 cm CTDI phantom may serve as the basis
69 for an SSDE for helical, head exams for normalized brain parenchyma doses for the three regions
70 investigated in this study. AAPM Report 204 conversion factors are however not applicable when the
71 definition of center of the scan volume includes cortical bone and therefore requires a different metric such
72 as mass-weighted average dose.

73

74 **Keywords: Size-specific dose estimate, Monte Carlo dose simulations, head CT**

75

76

77 **1. INTRODUCTION**

78 Between the years 1993 and 2006, 67×10^6 CT procedures were performed in the United States
79 with head procedures accounting for 28.4% of the total.¹ A recent study conducted by the University of
80 California Dose Optimization and Standardization Endeavor summarizing CT doses across twelve
81 University of California medical centers found that head scans comprised 16% of all adult CT
82 examinations.² The same study also found that most frequent area imaged in pediatric patients was the head,
83 accounting for 33% of the total procedures administered.² The fact that radiation exposure from head CTs
84 is a large contributor to total medical radiation exposures underscores the need for accurate patient dose
85 assessments from head CT procedures, particularly for younger patients.

86 The radiation dose metric commonly reported on most scanners is the volume computed
87 tomography dose index ($CTDI_{vol}$).^{3, 4} This metric, however, is a measure of dose to a reference phantom,
88 not a measure of patient dose.^{3, 4} Turner et al. showed that utilizing $CTDI_{vol}$ as normalization metric for
89 Monte Carlo (MC) simulated organs doses from abdominal CT scans compensated both for the differences
90 among scanner manufacturers and reduced the variation of organ doses across scanners from 31.5% down
91 to 5.2%.⁵ Subsequently, AAPM Report 204 developed the size-specific dose estimate (SSDE) quantity to
92 adjust $CTDI_{vol}$ using a set of $CTDI_{vol}$ -to-patient-dose conversion coefficients from either the 32 cm or 16
93 cm CTDI reference phantom to account for patient size in adult and pediatric body CT exams, respectively.⁶
94 SSDE represents an average dose to the “center of a scan volume” as defined by AAPM Report 204.⁶
95 Although SSDE has been shown to be a good substitute for organ dose in the context of abdominal scans,⁷
96 the work of AAPM Report 204 was limited only to body CT examinations.

97 The work of McMillan et al. in 2014 sought to extend the approach developed by Turner et al. and
98 used in AAPM Report 204 for the body, to investigate organs of interest in the head, including brain and
99 lens of eye, for routine helical and axial acquisitions.⁸ In that study, strong predictive exponential
100 correlations were observed when MC simulated organ doses from detailed voxelized phantom were
101 normalized by 16 cm $CTDI_{vol}$ and were parameterized by water equivalent diameter (D_w) as a metric of
102 patient size,⁹ yielding coefficients of determination (R^2) of 0.93 for whole brain dose for helical cans.⁸

103 While predictive correlations were determined in McMillan et al., that work focused on organ doses rather
104 than dose to the center of the scan volume, the latter being consistent with SSDE as defined in AAPM
105 Report 204.⁶


106 Therefore, the purpose of this current study is to estimate dose to the “center of the scan volume”
107 for helical head CT exams that can be used to determine conversion factors for an SSDE for the head. This
108 work will employ voxelized patient models along with MC simulation techniques with mesh tallies of the
109 entire head to produce voxelized dose distributions wherein two different interpretations of “center of the
110 scan volume” will be investigated: a small central region within the brain parenchyma and a central slab
111 comprising both brain parenchyma and cortical bone. Additionally, the entire scan volume was also
112 investigated. In the case of the central slab, as well for the entire scan volume, doses both to the brain
113 parenchyma and cortical bone will also be estimated. In order to take into consideration the dose received
114 both by brain parenchyma and cortical bone in the head, a mass weighted-average dose comprising both
115 brain parenchyma and cortical bone was devised to account for the presence both of brain parenchyma and
116 cortical bone within the slab tally region, as well as for the entire scan volume. Per AAPM Report 204, all
117 doses will be normalized by 16 cm $CTDI_{vol}$ and will be parameterized in an exponential fashion with D_w .

118 **2. MATERIALS AND METHODS**

119 **2.A Patient models**

120 Ten voxelized phantom models from the GSF family¹⁰ and ICRP voxelized reference male and
121 female^{11, 12} were used that have all of the radiosensitive organs identified. The eight GSF voxel-based
122 models were created from high-resolution CT images with up to 131 organs and anatomic structures
123 segmented and the two ICRP reference male and female voxelized models were each based off
124 modifications of two corresponding male and female GSF models of similar external dimensions.
125 Incorporation into MC simulations required each model be represented as a three-dimensional matrix of
126 organ or non-anatomic material such as air and the patient table as integer identification numbers wherein
127 each identification number was allocated a material description based on elemental compositions of tissue
128 substitutes and their densities as defined in ICRU Report 44.¹³

129 Additionally, to extend this investigation into the pediatric size range, the adult models were
130 augmented with five voxelized patient models created from the image data of pediatric patients (obtained
131 from clinically indicated scans and whose data was anonymized and collected under IRB approval), **Figure**
132 **1**. All scans were acquired on a Siemens Sensation 64 MDCT and were performed in the supine position.
133 To create voxelized models of each patient's anatomy from the image data, voxels within each image series
134 were modeled as either fat, water, muscle, bone or air and were subdivided into one of seventeen density
135 levels depending on its CT number.¹⁴ Individual organs were not segmented for these patient models but
136 brain parenchyma tissue was semi-automatically contoured and explicitly identified. The MCNPX model
137 characteristics for all voxelized models used in this study are summarized in **Table I**.



138

139 **Figure 1:** (Left) Head CT image of a pediatric patient who underwent a routine head exam. (Right)
 140 Monte Carlo representation of the patient wherein using a Hounsfield lookup table

141

142 **Table I:** MCNPX model resolution characteristics of GSF/ICRP and patient* voxelized models

Name	Gender	Age	In-plane resolution	Image slices	Column width (cm)	Row depth (cm)	Slice thickness (cm)
Peds1*	Male	7 wk	128 × 128	24	0.35	0.35	0.48
Baby	Female	8 wk	67 × 69	142	0.34	0.17	0.40
Peds2*	Male	7 d	128 × 128	30	0.35	0.35	0.48
Peds3*	Female	21 mo	128 × 128	36	0.39	0.39	0.48
Peds4*	Male	2 yr	128 × 128	30	0.35	0.35	0.48
Irene	Female	32 yr	66 × 66	348	0.75	0.38	0.50
Peds5*	Male	23 mo	128 × 128	30	0.35	0.35	0.48
Child	Female	7 yr	64 × 64	144	0.62	0.62	0.80
Helga	Female	28 yr	64 × 64	114	0.78	0.78	1.00
Golem	Male	38 yr	64 × 64	220	0.83	0.83	0.80
Donna	Female	40 yr	64 × 64	179	0.75	0.75	1.00
Frank	Male	48 yr	64 × 64	193	0.59	0.59	0.50
Visible Human	Male	38 yr	64 × 64	250	0.86	0.43	0.50
Regina	Female	38 yr	75 × 69	348	0.71	0.36	0.48
Rex	Male	43 yr	64 × 64	222	0.86	0.43	0.80

143

144 * Indicates a voxelized patient model created from image data obtained from clinically indicated scans

145

146 **2.B. CT scanner and scanning protocol**

147 The scanning protocol used in this investigation was taken from AAPM's Adult Routine Head CT

148 protocol.¹⁵ All simulations were performed as fixed tube current helical scans with the voxelized models

149 centered within the gantry and with the patient table removed. Per the guidelines outline by AAPM for
 150 Siemens scanners and the pitch was set to 0.55. The scan range was defined from the top of the C1 lamina
 151 through the top of the calvarium.¹⁵ The scan lengths for the GSF/ICRP phantom models⁸ and the five
 152 pediatric voxelized models can be found in **Table II**. The collimation for the simulations was set to the
 153 widest nominal setting available of 28.8 mm (measure beam width of 32.2 mm) as the most dose efficient
 154 collimation for this scanner. The AAPM's Routine Head CT protocol recommend either the gantry or head
 155 be tilted to reduce the dose to the lens of the eye;¹⁵ however, for the scanner being modeled, helical scans
 156 are not performed with gantry tilt, so no tilt angle was used in these simulations.

157

158 **Table II: Scan lengths used in this investigation**

Name	Scan length (cm)
Peds1	11.6
Baby	10.2
Peds2	14.3
Peds3	16.7
Peds4	14.5
Irene	15.8
Peds5	14.8
Child	14.8
Helga	14.5
Golem	15.6
Donna	16.5
Frank	21.8
Vishum	15.3
Regina	17.1
Rex	16.0

159

160 **2.D Size Metrics**

161 Water equivalent diameter (D_w) is an attenuation-based size metric described in AAPM Report
 162 220 and was used in this study as a measure of patient size.⁹ For the five pediatric patients, D_w was
 163 estimated at the center of the scan volume directly from the Hounsfield units in their image data. For the

164 GSF/ICRP models, it is not possible to directly calculate D_w since they are constructed with pixel data
 165 containing tissue identification numbers, not Hounsfield units. The D_w estimates for GSF/ICRP voxelized
 166 phantoms were instead obtained indirectly from a correlation between effective diameter and D_w .⁸ **Table**
 167 **III** contains the head D_w estimates for all fifteen patients used in this investigation.

168

169 **Table III:** Head D_w estimates for the GSF/ICRP and five pediatric voxelized models from patient data

Name	D_w (cm)
Peds1	10.6
Baby	11.1
Peds2	12.6
Peds3	15.6
Peds4	15.7
Irene	17.1
Peds5	17.1
Child	17.2
Helga	18.2
Golem	18.3
Donna	18.7
Frank	19.2
Visible Human	19.6
Regina	19.9
Rex	20.2

170

171

172

173 **2.D Monte Carlo simulations**

174 All CT dose simulations for this investigation were conducting using a modified version of the
 175 radiation transport software package MCNPX (Monte Carlo N-Particle eXtended version 2.7.a).¹⁶⁻¹⁸ All
 176 MC CT dosimetry for helical head scans were performed using an equivalent source model of the Siemens
 177 Sensation 64 multi-detector row CT (MDCT) scanner.²¹ The equivalent source model, as previously
 178 described by Turner et al., generates and incorporates scanner-specific X-Ray spectra and bowtie filter
 179 profiles.²¹

180 Voxelized dose distributions of the entire head of each voxelized model were produced using the
181 track-averaged rectangular mesh tally configuration (RMESH) within MCPNX wherein particles are
182 tracked through a mesh grid that is independent of the regular transport problem.¹⁶ The mesh tally grid was
183 consistent with the resolution of each individual voxelized and was overlapped with the voxel resolution of
184 the patient model to ensure doses on a per voxel basis were accurately estimated. The average energy
185 deposition within each voxel were in terms of MeV/cm³/source particle.¹⁶ Since the mesh tally configuration
186 is independent of the actual problem geometry, the resulting energy voxel-wise deposition maps were
187 divided by a density map created from the conversion of tissue identification numbers from the MCPNX
188 input files into corresponding density values to get units of MeV/g/source particle.

189 Normalization factors are necessary to convert dose per simulated particle (mGy/particle) to
190 absolute dose per tube current time product (mGy/mAs). To achieve this, all MCPNX tally results were
191 multiplied by a scanner, collimation, and beam energy specific normalization factor.²⁰ Each simulation was
192 performed with 10⁸ photons to ensure a relative error of less than 2% for each individual mesh element.

193

194 **2.E CTDI_{vol} measurements**

195 Conventional CTDI₁₀₀ exposure measurements were taken at the center and peripheral position of
196 a 16 cm CTDI head phantom with the scanning parameters in Sec 2.B. Exposure measurements in
197 milliroentgen (mR) were made with a standard 100 mm pencil ionization chamber and calibrated
198 electrometer and were thereafter converted to dose to air in mGy using the conversion factor 1 mR =
199 0.00876 mGy. Dose to air was then normalized by the tube current-rotation time product (mAs) used to
200 take the initial measurements. CTDI_{vol} was then calculated from the CTDI₁₀₀ measurements at the central
201 and peripheral locations and was recorded on a dose per tube current-time product basis (mGy/mAs).

202

203


204 **2.F Dose analyses**

205 All dose values to all voxels in the patient models were obtained using mesh tallies as outlined in
 206 Sec 2.D. Three regions were investigated in this study: (1) a small 0.6 cc volume at the center of the scan
 207 volume, (2) 0.8-1.0 cm axial slab at the center of the scan volume, and (3) the entire scan volume. A
 208 representation of each tally region is shown in **Figure 2**. Tally regions (1) and (2) were investigated as
 209 separate interpretations representing “center of the volume.” For tally region (1), a 0.6 cc volume was
 210 positioned at the center of scan volume and the mean brain parenchyma dose within this small volume were
 211 averaged and the associated standard deviation and coefficient of variations were recorded. This
 212 configuration was used to mimic a dose reading from the irradiation of 0.6 cc ion chamber virtually located
 213 in the center of head. In this last configuration, since the tally region is located in center of scan volume in
 214 the brain, only mean dose, standard deviations, and coefficients of variations for the brain parenchyma were
 215 measured. For tally region (2), dose mesh elements within a slab along an axial plane at the center of the
 216 scan volume were identified. The thickness of the slab consisted of one to two slices along the longitudinal
 217 axis of the phantom, ranging from 0.8 – 1.0 cm, depending on the slice thickness of the voxelized phantom,
 218 as detailed in Table I in Sec 2.A. The slab captures dose to the brain parenchyma, as well as dose to the
 219 cortical bone surrounding it. Under this configuration, the mean doses to both brain parenchyma and cortical
 220 bone within the slab were calculated. Standard deviation and coefficient of variation for both brain
 221 parenchyma and cortical bone within the slab were also calculated. Additionally, a mean mass-weighted
 222 average of dose contributions from both brain tissue and bone was calculated using **Equation 1**,

$$D_{wt-avg} = \frac{D_{bone}M_{bone} + D_{brain}M_{brain}}{M_{bone} + M_{brain}} \quad (1)$$

224 where D_{bone} and D_{brain} are the mean dose contributions from bone and brain parenchyma, respectively, and
 225 M_{bone} and M_{brain} represent the mass contributions from bone and brain parenchyma, respectively. Similarly,
 226 the mean doses of both brain parenchyma and cortical bone within the entire scan volume were calculated,
 227 as well as a mean mass-weighted average dose. Standard deviations and coefficients of variation for brain
 228 parenchyma and cortical bone doses within the entire scan volume were also recorded. In this study, mean
 229 doses are designated with the notion $D_{tissue,tally\ region}$ where *tissue* represents the tissue type and *tally region*

230 represents one of the three tally regions. The tissue contents and doses calculated within each tally region
 231 are summarized in **Table IV**.



232
 233 **Figure 2:** MCNPX voxelized representation of ICRP male “Rex” depicting **A)** the 0.6 cc volume positioned
 234 at the center of scan volume (tally region 1), **B)** the 0.8-1.0 cm axial slab positioned at the center of the scan
 235 volume (tally region 2), and **C)** the entire scan volume (tally region 3) as specified by the AAPM Routine
 236 Head CT¹⁵ protocols with corresponding color-coded material designation for each voxel.

237
 238
 239 **Table IV:** Summary of tally regions, tissue contents within each tally region, and mean dose estimates
 240 measured

Tally region	Tissue(s) in tally region	Doses calculated
0.6 cc volume (1)	Brain parenchyma	$D_{\text{brain},1}$
Central slab (2)	Brain parenchyma, cortical bone	$D_{\text{brain},2}, D_{\text{bone},2}, D_{\text{wt-avg},2}$
Entire scan volume (3)	Brain parenchyma, cortical bone	$D_{\text{brain},3}, D_{\text{bone},3}, D_{\text{wt-avg},3}$

241
 242 All dose values were normalized by 16 cm $CTDI_{\text{vol}}$. Like AAPM Report 204, normalized dose
 243 values were parameterized as a function of D_w via an exponential relationship, as can be seen in **Equation**
 244 **2**,

245

$$\frac{D_{\text{tally region, tissue}}}{CTDI_{\text{vol}}} = A \times e^{-B \times D_w} \quad (2)$$

246 where A and B are regression constants for a given tissue classification. The coefficient of determination
247 (R^2) was used to assess the ability of the correlations to explain the proportion of variation explained by
248 D_w .

249 For the sake of comparison, brain parenchyma doses from all three tally regions were compared
250 with one another using an ANOVA analysis. An ANOVA analysis was also performed to compare
251 conversion factors from AAPM Report 204 for a 16 cm CTDI phantom with normalized brain parenchyma
252 dose from tally regions (1), (2), and (3). Cortical bone doses for tally regions (2) and (3) were compared
253 using a paired t-test. Similarly, mass-weighted average doses for tally regions (2) and (3) were also
254 compared using a paired t-test. An ANOVA analysis was also performed to compare conversion factors
255 from AAPM Report 204 with mass-weighted average doses from tally regions (2) and (3). All statistical
256 analyses were performed using GraphPad Prism 6.00 for Mac OS X (GraphPad Software, La Jolla,
257 California, USA, www.graphpad.com).

258

259

260 **3. RESULTS**


261 **3.A. Mesh tally results**

262 Three dose distribution maps from the mesh tally simulations are shown in **Figure 3**. These mesh tally
263 results provide a graphical representation of the uniformity of the dose distribution within the brain
264 parenchyma. Each of the following sections below describe the doses for each tissue group: brain
265 parenchyma followed by bone dose and the mass-weighted average of brain and bone dose.

266

267

268



269

270 **Figure 3:** Axial view of voxelized dose distribution maps for Peds3 (A), Peds4 (B), and Rex (C),
 271 respectively, at the top, center, and bottom of the scan volume. The red arrow at the top of the figure
 272 indicates the direction of the scan range. The maps were generated by aligning rectangular mesh tallies with
 273 the resolution of MCNPX geometry. Energy deposition was tallied on a per voxel basis. Mesh tally results
 274 were then divided by the voxelized tissue density. Scanner-specific, collimation-specific normalization
 275 factors were then used to convert MCNPX dose results to units of mGy/mAs.

276

277 3.A.1 Brain parenchyma doses

278 In this section, the dose to the brain parenchyma for all of the different regions is reported. $D_{\text{brain},1}$,
 279 $D_{\text{brain},2}$, and $D_{\text{brain},3}$, for each voxelized model can be seen in **Table V**, with ranges from 0.190 to 0.292
 280 mGy/mAs for $D_{\text{brain},1}$, 0.185 to 0.286 for $D_{\text{brain},2}$, and 0.178 to 0.284 for $D_{\text{brain},3}$. This table also shows that
 281 the coefficients of variation were below 2.6%, 6.5%, and 9.4% within tally regions (1), (2), and (3),
 282 respectively, across all voxelized models and below 3.9% across all tally regions within each voxelized
 283 model. ANOVA analysis with multiple comparison showed that $D_{\text{brain},1}$, $D_{\text{brain},2}$, and $D_{\text{brain},3}$ were not
 284 significantly different from each other ($F(2, 42) = 0.07$, $P = 0.93$).

285

286

287

288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303

304 **Table V:** Mean brain doses by tally region type with coefficients of variation within each tally region, and
 305 the coefficient of variation across tally regions for each patient

Name	0.6 cc volume (1)		Slab (2)		Entire scan volume (3)		Across Regions
	$D_{\text{brain},1}$ (mGy/mAs)	CV	$D_{\text{brain},2}$ (mGy/mAs)	CV	$D_{\text{brain},3}$ (mGy/mAs)	CV	CV
Peds1	0.290	1.7%	0.286	5.3%	0.284	4.8%	1.1%
Baby	0.292	1.4%	0.286	3.4%	0.283	5.6%	1.6%
Peds2	0.257	2.6%	0.254	4.2%	0.273	5.0%	3.9%
Peds3	0.230	2.5%	0.226	4.0%	0.238	7.3%	2.6%
Peds4	0.217	2.0%	0.215	4.8%	0.216	6.7%	0.5%
Irene	0.212	1.2%	0.210	5.6%	0.204	6.4%	2.0%
Peds5	0.200	2.6%	0.197	4.8%	0.197	5.9%	0.9%
Child	0.229	1.9%	0.227	2.9%	0.221	4.9%	1.8%
Helga	0.204	1.3%	0.207	4.8%	0.198	7.1%	2.3%
Golem	0.217	0.8%	0.211	5.0%	0.208	5.9%	2.2%
Donna	0.210	2.8%	0.214	4.4%	0.203	7.1%	2.7%
Frank	0.190	1.4%	0.185	5.0%	0.178	9.2%	3.3%
Visible Human	0.188	1.7%	0.187	6.5%	0.180	9.4%	2.4%
Regina	0.216	2.5%	0.215	5.3%	0.207	7.8%	2.3%
Rex	0.197	0.8%	0.195	3.9%	0.189	5.9%	2.1%

306

307 **3.A.2 Cortical bone doses**

308 $D_{\text{bone},2}$ and $D_{\text{bone},3}$, for each voxelized model, had ranges of 0.664 to 1.040 mGy/mAs and 0.604 to
309 0.957, respectively. $D_{\text{bone},2}$ and $D_{\text{bone},3}$ had coefficients of variation of less than 27% and 29% within each
310 tally region, respectively, and had differences of less than 13% across all models. Using a paired t-test,
311 $D_{\text{bone},2}$ and $D_{\text{bone},3}$ were found to be statistically different from each other ($t=7.95$, $P < 0.0001$). The results
312 for $D_{\text{bone},2}$ and $D_{\text{bone},3}$ are summarized in **Table VI**.

313

314

315

316

317

Table VI: Mean bone doses by tally region type with coefficients of variation within each tally region and percent difference between the means of each region

Name	Slab (2)		Entire scan volume (3)		
	$D_{\text{bone},2}$ (mGy/mAs)	CV	$D_{\text{bone},3}$ (mGy/mAs)	CV	%Difference
Peds1	0.917	27%	0.894	29%	2.5%
Baby	1.040	6%	0.957	14%	8.6%
Peds2	0.929	8%	0.916	11%	1.4%
Peds3	0.839	16%	0.768	21%	9.2%
Peds4	0.759	18%	0.731	24%	3.9%
Irene	0.730	9%	0.697	12%	4.8%
Peds5	0.857	14%	0.768	19%	12%
Child	0.792	5%	0.733	15%	8.1%
Helga	0.734	10%	0.651	16%	13%
Golem	0.723	8%	0.688	15%	5.2%
Donna	0.750	9%	0.680	13%	10%
Frank	0.664	10%	0.604	17%	10%
Visible Human	0.673	13%	0.603	18%	12%
Regina	0.730	9%	0.693	11%	5.4%
Rex	0.661	8%	0.636	11%	3.9%

318

319

320 **3.A.3 Mass-weighted average**

321 $D_{wt-avg,2}$ and $D_{wt-avg,3}$, for each voxelized model, had ranges of 0.306 to 0.397 mGy/mAs and 0.380
322 to 0.472, respectively. $D_{wt-avg,2}$ and $D_{wt-avg,3}$ had a difference of less than 24% across all patient models with
323 $D_{wt-avg,3}$ consistently having the larger value across all patient models and all sizes. These differences were
324 statistically different using a paired t-test ($t=15.89$, $P < 0.0001$). The results for $D_{wt-avg,2}$ and $D_{wt-avg,3}$ are
325 shown in **Table VII**.

326

327

328

Table VII: $D_{wt-avg,2}$, $D_{wt-avg,3}$, and percent difference between the means

Name	Slab (2)	Entire scan volume (3)	% Difference
	$D_{wt-avg,2}$ (mGy/mAs)	$D_{wt-avg,3}$ (mGy/mAs)	
Peds1	0.366	0.436	-16%
Baby	0.397	0.472	-16%
Peds2	0.338	0.412	-18%
Peds3	0.359	0.399	-10%
Peds4	0.326	0.395	-17%
Irene	0.328	0.417	-21%
Peds5	0.326	0.408	-20%
Child	0.324	0.397	-18%
Helga	0.311	0.398	-22%
Golem	0.351	0.411	-15%
Donna	0.350	0.427	-18%
Frank	0.361	0.401	-10%
Vishum	0.332	0.380	-13%
Regina	0.306	0.402	-24%
Rex	0.317	0.379	-16%


329

330

331 **3.B Size-specific, scanner-independent dose estimates**

332 **3.B.1 Normalized brain parenchyma doses and comparison with AAPM Report 204 values**

333 **Figure 4** shows normalized $D_{\text{brain},1}$, $D_{\text{brain},2}$, and $D_{\text{brain},3}$ parameterized as functions of D_w , along
334 with AAPM Report 204 conversion coefficients for the 16-cm pediatric body phantom. The coefficients of
335 determination for normalized $D_{\text{brain},1}$, $D_{\text{brain},2}$, and $D_{\text{brain},3}$ were 0.86, 0.84, and 0.88, respectively. Results
336 from the regression analysis are summarized in **Table VIII**. ANOVA analysis showed there was no
337 statistically significant difference between the means $D_{\text{brain},1}$, $D_{\text{brain},2}$, $D_{\text{brain},3}$, and AAPM Report 204
338 conversion factors based on 16 cm CTDI_{vol} [$F(3, 56) = 0.70, P = 0.56$]. The differences between $D_{\text{brain},1}$,
339 $D_{\text{brain},2}$, and $D_{\text{brain},3}$ estimates using results from the regression analysis and AAPM report 204 conversion
340 factors were less than 5.7%, 8.4%, and 8.6%, respectively. It should be noted that the estimates based on
341 AAPM Report 204 were consistently higher than those resulting from our Monte Carlo simulations, though
342 by less than 10%.



343

344 **Figure 4:** Normalized $D_{\text{brain},1}$, $D_{\text{brain},2}$, and $D_{\text{brain},3}$ with associated regression fits. AAPM Report 204
345 conversion factors based 16 cm CTDI_{vol} is also plotted for comparison.

346

347

348

349

350

351
352

Table VIII: Regression analysis results for $D_{\text{brain},1}$, $D_{\text{brain},2}$, and $D_{\text{brain},3}$, and with AAPM Report 204 regression curve coefficients


Normalized dose	A	B	R^2
$D_{\text{brain},1}$	1.80	0.041	0.86
$D_{\text{brain},2}$	1.74	0.041	0.84
$D_{\text{brain},3}$	1.93	0.046	0.88
AAPM Report 204	1.87	0.039	-

353

354 **3.B.2 Normalized bone doses**

355 **Figure 5** contains normalized $D_{\text{bone},2}$ and $D_{\text{bone},3}$ parameterized as functions of D_w . The coefficients
356 of determination for normalized $D_{\text{bone},2}$ and $D_{\text{bone},3}$ were 0.83 and 0.87, respectively. Results of the regression
357 analysis are tabulated in **Table IX**.

358



359

Figure 5: Normalized $D_{\text{bone},2}$ and $D_{\text{bone},3}$ with associated regression fits.

360

361

362

Table IX: Regression analysis for normalized $D_{\text{bone},2}$ and $D_{\text{bone},3}$

Normalized Dose	A	B	R^2
$D_{\text{bone},2}$	6.17	0.039	0.83
$D_{\text{bone},3}$	6.17	0.043	0.88

363

364

365

366

367

368 **3.B.3 Normalized weighted average doses and comparisons to AAPM Report 204 values**

369
370 **Figure 6** shows normalized $D_{wt-avg,2}$ and $D_{wt-avg,3}$ parameterized as functions of D_w . The coefficients

371 of determination for normalized $D_{wt-avg,2}$ and $D_{wt-avg,3}$ were 0.39 and 0.51, respectively. An ANOVA analysis


372 between AAPM Report 204 conversion factors and normalized $D_{wt-avg,2}$ and $D_{wt-avg,3}$ showed a statistically

373 significant difference [$F(2,42) = 168.1, P < 0.0001$]. Results from the regression analysis are summarized

374 in **Table X**. It should be noted here that the AAPM Report 204 values are consistently lower than the D_{wt-}

375 $_{avg,2}$ and $D_{wt-avg,3}$ values shown in Figure 6.

376
377



378
379

380 **Figure 6:** Normalized $D_{wt-avg,2}$ and $D_{wt-avg,3}$ with associated regression fits. AAPM Report 204 conversion
381 factors based 16 cm $CTDI_{vol}$ is also plotted for the sake of comparison.

382
383
384
385

Table X: Regression analysis for normalized $D_{wt-avg,2}$ and $D_{at-avg,3}$

Normalized Dose	<i>A</i>	<i>B</i>	<i>R</i> ²
$D_{wt-avg,2}$	1.76	0.014	0.39
$D_{at-avg,3}$	2.08	0.013	0.51

386

387 **4. DISCUSSION**

388 In this study, Monte Carlo simulation methods were performed to obtain estimates of brain and
389 bone dose from patients of different sizes and different tally configurations that could be used as a basis for
390 determining SSDE conversion coefficients for routine, helical head examinations. Two different tally
391 configurations were considered as possible candidates for the condition that measure dose be in the “center
392 scan volume” as described by AAPM Report 204⁶, in addition to tallying the entire scan volume of each
393 patient. A mass-weighted average dose quantity was used to take the presence of cortical bone into
394 consideration for the central slab configuration, as well for the entirety of the scan volume. Lastly,
395 normalized brain parenchyma doses under all the three tally configurations and normalized mass-weighted
396 average dose quantity for the both slab and the entire scan volume were compared with conversion
397 coefficients from AAPM Report 204 for 16 cm pediatric body phantom.

398 Normalized $D_{\text{brain},1}$, $D_{\text{brain},2}$, and $D_{\text{brain},3}$ had R^2 of 0.86, 0.84 and 0.88, respectively, indicated that
399 D_w provides good correlative function for the normalized brain parenchyma doses under the configurations
400 investigated in this study, including the for the entirety of the scan volume, as was also shown in McMillan
401 et al.⁸ Unlike the study conducted by McMillan et al., which only investigated normalized organ doses,⁸ the
402 current study employed meshed tallies to map dose distributions on a per voxel basis. Using this approach,
403 $D_{\text{brain},1}$, $D_{\text{brain},2}$, and $D_{\text{brain},3}$ were found to be homogeneous with CVs below 10% across all voxelized models
404 and below 4% across all tally regions within each voxelized model. $D_{\text{brain},1}$, $D_{\text{brain},2}$, and $D_{\text{brain},3}$ estimates
405 from regression fits and AAPM Report 204 conversion factors had differences below 10% for all three
406 configurations. Additionally, normalized $D_{\text{brain},1}$, $D_{\text{brain},2}$, and $D_{\text{brain},3}$ were not significantly different than
407 AAPM Report 204 conversion factors for 16 cm CTDI ($P = 0.56$). The implication of this result is that if
408 “center of the scan volume” is defined as a small, central volume or a central slab within the brain
409 parenchyma, then normalized doses within this region, as well as whole brain dose, could be reasonably
410 estimated using the SSDE conversion coefficients from the 16 cm phantom values from AAPM Report 204.
411 The differences observed between AAPM Report 204 and normalized $D_{\text{brain},1}$, $D_{\text{brain},2}$, and $D_{\text{brain},3}$ can be
412 attributed to the fact that the AAPM Report 204 conversion factors were originally devised to estimate dose

413 to the center of the scan volume for the abdomen, which is homogenous region comprised of soft tissue.
414 The head, in contrast, is comprised of the soft-tissue brain parenchyma encased in cortical bone. The
415 presence of the cortical bone provides an inherent source of shielding for the brain parenchyma, which
416 decreases the normalized dose of the brain parenchyma relative to the normalized dose to the center of the
417 scan volume for the abdomen.

418 $D_{\text{bone},2}$ and $D_{\text{bone},3}$ doses had coefficient of variation of upwards of 29% and 27%, respectively.
419 Variations of surface dose as high as 30% for helical scans were previously observed by the Zhang et al. as
420 a consequence of wider beam collimations and tube start angle.²² When investigating the surface dose
421 profile of a 32 cm CTDI phantom using MC, for example, Zhang et al. noted substantial dose peaks when
422 utilizing a pitch of less than one and when the simulated beam width were wider than the nominal beam
423 width.²² A similar effect was seen when investigating the variability of surface dose in anthropomorphic
424 phantoms in the abdominal and thoracic regions whereby, a pitch 0.75 resulted in a 37% increase in surface
425 dose was shown.²² The results of this study indicate that the variations observed within dose voxels of the cortical
426 bone could be due to surface dose variations, particularly given the use of the low pitch and wide beam
427 collimations recommended in the AAPM's Adult Routine Head CT Protocol.¹⁵

428 The coefficients of determination for normalized $D_{\text{bone},2}$ and $D_{\text{bone},3}$ were 0.83 and 0.87, respectively,
429 indicating, as with normalized $D_{\text{brain},1}$, $D_{\text{brain},2}$, and $D_{\text{brain},3}$, D_w provides good correlative function for
430 normalized cortical bone dose either for the entirety of the head or for a central slab. The motivation for
431 investigating dose to cortical bone as a function of patient size comes from the fact that, within the cranium,
432 there is a fair amount of active red bone marrow (RBM), particularly in pediatric patients, with the active
433 marrow percentage being 12% for children 10 years age and up to 29%-27% for infant patients.^{23, 24} The
434 cranium is composed of the inner and outer layers of cortical bone that enclose bone spongiosa, wherein
435 RBM, yellow bone marrow (YBM), and trabecular bone are found.²⁴ Active RBM is the primary tissue of
436 interest for the radiogenic risk of leukemia and is considered highly radiosensitive, as reflected by the tissue
437 weighting designation in ICRP 103 ($w_T = 0.12$).²⁵ In this study, RBM and YBM were not modeled. The
438 cranial microdosimetry necessary to accurately assess dose RBM is beyond the scope of this study, as is

439 assessing the leukemia risk associated with head CT procedures, since SSDE was only intended to estimate
440 patient dose using metrics of radiation output displayed by scanners and was not intended to assess cancer
441 risk from CT procedures.⁶ In routine head exams, such as those recommended in AAPM's Adult Routine
442 Head CT Protocol,¹⁵ though the cortical bone would provide some shielding for the spongiosa containing
443 RBM, RBM within the cranium could nevertheless be irradiated. The potential effects of RBM dose should
444 be taken into consideration as a consequence of the scanning techniques used in routine head exams,
445 particularly for pediatric patients.^{25, 26}

446 In accordance with the second interpretation of "center of scan volume," this study also investigated
447 dose to a central slab of head, which consists of both cortical bone and brain parenchyma. A mass weighted-
448 average of the dose contributions of both cortical bone and brain parenchyma was devised to take into
449 consideration the presence of both tissue types. The coefficients of determination for normalized $D_{wt-avg,2}$
450 and $D_{wt-avg,3}$ were 0.39 and 0.51, respectively. The loss of exponential relationship effects with respect to
451 the normalized mass-weighted average dose and patient size can be explained by considering relationship
452 between bone mass (and tissue mass) fraction of the head as a function of patient size. The mass of cortical
453 bone increases with age which competes with the decreasing exponential of normalized dose versus patient
454 size. Weighting normalized doses of brain parenchyma and cortical bone by their respective masses
455 accounts for the effects of size of the patients in effect, making the relationship of normalized weighted
456 average dose more linear with respect to patient size.

457 In summary, the aim of this study was to develop conversion coefficients for routine helical head
458 CT procedures using MC methods and voxelized patient models for two interpretations of "center of the
459 scan volume" that may be used in a manner similar to those described in AAPM Report 204.⁶ ANOVA
460 analysis employed herein comparing AAPM Report 204 conversion factors based on 16 cm CTDI phantom
461 with normalized brain parenchyma dose to a central point, a central slab, or the entire scan volume, revealed
462 that the conversion factors found in AAPM Report 204 can be used as a basis for head SSDE only if dose
463 to the brain parenchyma is considered. On the other hand, the conversion coefficients in AAPM Report 204
464 are not applicable when the definition of center of the scan volume includes dose to cortical bone. A

465 different metric, such as mass-weighted average dose, is needed to assess the dose contributions of both
466 tissue types.

467

468 **REFERENCES**

- 469 ¹ F.A. Mettler *et al.*, “Radiologic and Nuclear Medicine Studies in the United States and
470 Worldwide: Frequency, Radiation Dose, and Comparison with Other Radiation Sources—1950–
471 2007,” *Radiology* **253**(2), 520–531 (2009).
- 472 ² R. Smith-bindman *et al.*, “Radiation Doses in Consecutive CT Examinations from Five University
473 of California Medical Centers,” *Radiology* **0**(0), 1–8 (2015).
- 474 ³ C.H. McCollough, “CT dose: how to measure, how to reduce.,” *Health Phys.* **95**(5), 508–17
475 (2008).
- 476 ⁴ M.F. McNitt-Gray, “AAPM/RSNA Physics Tutorial for Residents: Topics in CT Radiation Dose
477 in CT1,” *Radiographics* **22**(6), 1541–1553 (2002).
- 478 ⁵ A.C. Turner *et al.*, “The feasibility of patient size-corrected, scanner-independent organ dose
479 estimates for abdominal CT exams.,” *Med. Phys.* **38**(2), 820–9 (2011).
- 480 ⁶ AAPM Report 204, *Size-Specific Dose Estimates (SSDE) in Pediatric and Adult Body CT*
481 *Examinations* (College Park, MD, 2011).
- 482 ⁷ B.M. Moore, S.L. Brady, A.E. Mirro, and R.A. Kaufman, “Size-specific dose estimate (SSDE)
483 provides a simple method to calculate organ dose for pediatric CT examinations,” *Med. Phys.*
484 **41**(7), 1–10 (2014).
- 485 ⁸ K. McMillan, M. Bostani, C. Cagnon, M. Zankl, A.R. Sepahdari, and M. McNitt-Gray, “Size-
486 specific, scanner-independent organ dose estimates in contiguous axial and helical head CT
487 examinations,” *Med. Phys.* **41**(12), 121909 (2014).
- 488 ⁹ AAPM Task Group 220, *Use of Water Equivalent Diameter for Calculating Patient Size and Size-
489 Specific Dose Estimates (SSDE) in CT* (College Park, MD, 2014).
- 490 ¹⁰ N. Petoussi-Henss, M. Zankl, U. Fill, D. Regulla, and M. Zankl, “The GSF family of voxel

491 phantoms,” *Phys. Med. Biol.* **47**(1), 89–106 (2002).

492 ¹¹ International Commission on Radiological Protection, “Adult reference computational phantoms,”
493 ICRP Publ. 110. *Ann. ICRP* **39** (2), (2009).

494 ¹² M. Zankl, K.F. Eckerman, and W.E. Bolch, “Voxel-based models representing the male and
495 female ICRP reference adult - The skeleton,” *Radiat. Prot. Dosimetry* **127**(1–4), 174–186 (2007).

496 ¹³ ICRU, “ICRU Report 44, Tissue Substitutes in Radiation Dosimetry and Measurement,” *J. Int.*
497 *Comm. Radiat. Units Meas.* (1993).

498 ¹⁴ J.J. Demarco, T.D. Solberg, and J.B. Smathers, “A CT-based Monte Carlo simulation tool for
499 dosimetry planning and analysis,” *Med. Phys.* **25**, 1–11 (1998).

500 ¹⁵ American Association of Physicists in Medicine, *Adult Routine Head CT Protocols Version 2.0*,
501 1–20 (2016).

502 ¹⁶ D.B. Pelowitz, “MCNPX User’s Manual,” in *MCNPX User’s Man.*(Los Alamos, NM, 2011).

503 ¹⁷ AAPM Task Group 195, *Monte Carlo Reference Data Sets for Imaging Research* (College Park,
504 MD, 2015).

505 ¹⁸ M. Bostani *et al.*, “Accuracy of Monte Carlo simulations compared to in-vivo MDCT dosimetry.,”
506 *Med. Phys.* **42**(2), 1080 (2015).

507 ¹⁹ M.B. Chadwick *et al.*, “ENDF/B-VII.1 nuclear data for science and technology: Cross sections,
508 covariances, fission product yields and decay data,” *Nucl. Data Sheets* **112**(12), 2887–2996
509 (2011).

510 ²⁰ J.J. DeMarco *et al.*, “A Monte Carlo based method to estimate radiation dose from multidetector
511 CT (MDCT): cylindrical and anthropomorphic phantoms.,” *Phys. Med. Biol.* **50**(17), 3989–4004
512 (2005).

513 ²¹ A.C. Turner *et al.*, “A method to generate equivalent energy spectra and filtration models based on
514 measurement for multidetector CT Monte Carlo dosimetry simulations.,” *Med. Phys.* **36**(6), 2154–
515 2164 (2009).

516 ²² D. Zhang *et al.*, “Variability of surface and center position radiation dose in MDCT: Monte Carlo

517 simulations using CTDI and anthropomorphic phantoms.," Med. Phys. **36**(3), 1025–38 (2009).

518 ²³ ICRP 70, "Basic Anatomical & Physiological Data for use in Radiological Protection - The
519 Skeleton," Ann. ICRP (2), (1995).

520 ²⁴ M. Cristy, "Active bone marrow distribution as a function of age in humans.," Phys. Med. Biol.
521 **26**, 389–400 (1981).

522 ²⁵ ICRP, "The 2007 Recommendations of the International Commission on Radiological Protection,"
523 ICRP Publ. 103. Ann. ICRP 37 (2007).

524 ²⁶ M.S. Pearce *et al.*, "Radiation exposure from CT scans in childhood and subsequent risk of
525 leukaemia and brain tumours: A retrospective cohort study," Lancet **380**(9840), 499–505 (2012).

526